The ISCT 2019 Early Stage Professional Abstract Award is given to individuals within 10 years of receiving their terminal degrees or entry into the cell and gene therapy field, who provide top-scoring abstracts. Akron is proud to present one of these three ESP awards to David Bishop, BMedSc(Hons), MBBS, FRACP FRCPA, Westmead Hospital (Australia). Bishop’s
Scientists from Boston Children’s Hospital and Massachusetts Institute of Technology (MIT) have used alpaca-derived nanobodies to create a novel approach to CAR T cell therapy that addresses the challenge of treating patients with solid tumor cancers. Currently, CAR-T cell immunotherapy has been applied to the treatment of non-solid tumors such as acute lymphoblastic leukemia (ALL).
Following successful clinical studies, the FDA and regulatory authorities around the world have approved the use of axicabtagene ciloleucel (Yescarta™) for patients with large-B-cell lymphomas and tisagenlecleucel (Kymriah™) for adults with certain types of non-Hodgkin lymphoma. Despite its success as a novel way of treating cancer, physician scientists are realizing that 30%-50% of patients who
Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic
Recently published research findings suggest that we may be able to prevent Cytokine Release Syndrome (CRS) through the oral administration of an FDA-approved drug. CAR-T therapy is a promising new approach to cancer treatment. However, a devastating side effect of CAR-T cell infusion is CRS. The patient’s infused activated T cells release interferon gamma (IFN-γ)
Chimeric antigen receptor T cell (CAR T) therapies have proved remarkably effective against leukemia and lymphoma, but for these therapies to target other types of cancer, there are still hurdles to overcome. Brain cancer is particularly challenging for immunotherapies due to the blood-brain barrier. This semi-permeable barrier tightly regulates the homeostasis of the central nervous
As a scorching summer draws to a close and conference season begins, Akron will be participating at many upcoming events to further advocate for the use of higher quality ancillary materials in regenerative medicine processes. Our focus of providing affordable cGMP reagents throughout the development stages for these unique therapeutics serves to better ensure reproducibility
Chimeric antigen receptors (CARs) significantly enhance the anti-tumor activity of immune effector cells. Current CAR-based immunotherapies leverage engineered versions of a patient’s own T-cells to target and kill cancer cells. Recently, a study led by researchers at University of California San Diego School of Medicine and University of Minnesota demonstrated that similarly modified CAR constructs
T cells expressing chimeric antigen receptors (CAR T) are particularly promising for the treatment of refractory cancers. While Kymriah and Yescarta are FDA-approved for B-cell malignancies, safety and efficacy concerns remain across the cell therapy industry. Severe cytokine release syndrome triggered by T cell infusion is one of the urgent CAR T related downsides that needs
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have terrible prognoses and novel cell therapies provide a glimmer of hope. While the CAR T therapy known as Kymriah led to complete remission in over 90% of patients with advanced acute lymphoblastic leukemia (ALL), only 26% of CLL patients responded to it in clinical trials.